ABCB8 Knockout cell line (SU-DHL-1)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

ABCB8 (ATP binding cassette subfamily B member 8) encodes an ATP-dependent transporter localized to the mitochondrial inner membrane. ABCB8 is predicted to transport organic or inorganic molecules across the mitochondrial membrane and may contribute to mitochondrial metabolite and ion homeostasis. Its activity has also been linked to regulation of iron balance between mitochondria and the cytosol.

The SU-DHL-1 cell line was established in 1973 from the pleural effusion of a 10-year-old male patient. Originally diagnosed as diffuse histiocytic lymphoma, the tumor was subsequently reclassified as diffuse large cell lymphoma and later as malignant histiocytosis. According to the REAL/WHO classification, the cell line represents anaplastic large cell lymphoma (ALCL) and carries the t(2;5)(p23;q35) translocation resulting in an NPM1-ALK (NPM-ALK) fusion gene. SU-DHL-1 is used as a model for studying ALCL biology and ALK-associated oncogenic signaling.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.